Search
Browse
Statistics
Feeds

Cardiac and vascular involvement in protein misfolding diseases

Item Type:Review
Title:Cardiac and vascular involvement in protein misfolding diseases
Creators: Stamatelopoulos, Kimon, Georgiopoulos, Georgios, Aimo, Alberto, Aivalioti, Evmorfia, Bauer, Karen Carolyn, Tual-Chalot, Simon, Kraler, Simon, Bampatsias, Dimitrios, Nuvolone, Mario, Abdellatif, Mahmoud, Delialis, Dimitrios, Laske, Christoph, Briasoulis, Alexandros, Vlachopoulos, Charalambos, Tavernarakis, Nektarios, Vendruscolo, Michele, Emdin, Michele, Hoppe, Thorsten, Trougakos, Ioannis, Palladini, Giovanni, Kastritis, Efstathios, Maurer, Mathew S., Fontana, Marianna and Stellos, Konstantinos ORCID logoORCID: https://orcid.org/0000-0002-0194-0825
Abstract:Protein misfolding diseases impose a substantial and often under-recognized burden on both the heart and vasculature. In this Review, we outline how the failure of proteostasis drives oligomer toxicity, amyloid deposition and inflammation in cardiovascular tissues as well as microvascular injury and thrombosis, which culminate in cardiovascular dysfunction. We define the cardiovascular hallmarks of protein misfolding diseases, focusing on transthyretin amyloidosis and immunoglobulin light chain amyloidosis, and the disease-specific organ tropisms. We examine neurodegenerative proteinopathies affecting the heart-vascular-brain axis, highlighting how amyloid-β and α-synuclein accumulation contribute to dysautonomia, vascular dysfunction and adverse outcomes. We summarize diagnostic pathways and clinical indicators for early diagnosis of cardiovascular involvement in protein misfolding diseases and review established and emerging biomarkers of vascular stress and proteotoxic load. We also map the current therapeutic landscape for protein misfolding diseases, including strategies to reduce the synthesis of precursor proteins or promote the stabilization of mature proteins as well as fibril-directed therapies, and discuss remaining challenges, such as residual cardiovascular risk, that support the development of mechanism-informed therapeutic approaches. Finally, we propose a research roadmap that prioritizes systematic cardiovascular screening in at-risk populations, harmonized methods for vascular phenotyping, biomarker-anchored mechanistic clinical trials across protein misfolding diseases, and artificial intelligence-based approaches and precision medicine frameworks that integrate genotype or distinct protein conformational strain patterns, organ tropism and dynamic proteostasis measures.
Source:Nature Reviews Cardiology
ISSN:1759-5002
Publisher:Nature Publishing Group
Date:5 November 2026
Official Publication:https://doi.org/10.1038/s41569-026-01359-8
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library